ScienceKRAS G12D drug reportedly shrinks tumors in phase 1 pancreatic and lung cancer study
A post describing a Nature Medicine study reports tumor shrinkage in about 1 in 3 heavily pretreated patients taking GFH375/VS-7375, and grade 3 or higher treatment-related side effects in about a third.
TLDR
According to a post describing a phase 1 study in Nature Medicine, GFH375/VS-7375 is an oral drug designed specifically to target KRAS G12D. The post reports tumor shrinkage in about 1 in 3 heavily pretreated patients with pancreatic or lung cancer. For pancreatic cancer, it cites median progression-free survival of 5.5 months and median overall survival of 9.9 months. About a third of patients had grade 3 or higher treatment-related side effects. The author describes the findings as encouraging but still early.
Combined views
12.8K
1 Source, first seen 8d ago
KRAS G12D drug reportedly shrinks tumors in phase 1 pancreatic and lung cancer study
A post describing a Nature Medicine study reports tumor shrinkage in about 1 in 3 heavily pretreated patients taking GFH375/VS-7375, and grade 3 or higher treatment-related side effects in about a third.
TLDR
According to a post describing a phase 1 study in Nature Medicine, GFH375/VS-7375 is an oral drug designed specifically to target KRAS G12D. The post reports tumor shrinkage in about 1 in 3 heavily pretreated patients with pancreatic or lung cancer. For pancreatic cancer, it cites median progression-free survival of 5.5 months and median overall survival of 9.9 months. About a third of patients had grade 3 or higher treatment-related side effects. The author describes the findings as encouraging but still early.